Volume overload after PTA for central venous stenotic or occluded lesions in chronic hemodialysis patients resulted in increased RA and RV diameters. These changes were transient and completely recovered by the following day. PTA for central venous lesions in patients with normal EF can be performed without clinical cardiac problems.

Platypnea-orthodeoxia syndrome (POS) is a rare clinical condition defined by the presence of dyspnea and deoxygenation accompanying changing from a supine to an upright position. We experienced the case of a 75-year-old woman who developed severe acute dyspnea after a car accident. Detailed history taking and a physical examination offered important clues that helped to make an accurate diagnosis of POS. The mechanism of onset is unique and rare; however, it is important for clinical cardiologists to keep this possibility in mind when making a differential diagnosis.

No abstract

No abstract

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp he energy metabolism of the heart and the utilization of substrates including glucose, fatty acids, amino acids, lactic acid and ketone bodies depend on circumstances, 1 and are primarily based on fatty acid metabolism and glucose metabolism in a competitive manner. 2 However, a shift to anaerobic metabolism because of low oxygen supplies causes ischemic myocardium to primarily utilize glucose. 3,4 Many reports have discussed whether maintaining glucose metabolism is important in estimating the viability of ischemic myocardium, and some reports indicate that improvements in left ventricular function and the prevention of cardiac events are achieved with the use of aggressive revascularization procedures. 5-9 The use of glucose-loaded 18 F-fluoro-2-deoxyglucose ( 18 F-FDG) PET has played a central role in helping cardiovascular interventionalists decide whether revascularization procedures are indicated in patients with old myocardial infarction (MI) with residual stenosis and angina pectoris. 10-13 18 F-FDG-PET has been also utilized to evaluate systemic inflammatory diseases, including malignancies, because 18 F-FDG accumulates in sites of inflammation. 14,15 Therefore, appropriate timing for the evaluation of glucose-loaded 18 F-FDG-PET images of acute MI (AMI) has been conventionally considered T

No abstract

The restenosis rate of coronary stent has significantly decreased by implantation of the drug-eluting stent (DES). We often experienced the DES implantation for very small target vessels. The minimum size of DES in Japan and USA is 2.5 mm-diameter, but there were no reports of the expandability of DESs for the very small target vessels with reference diameter <2.2 mm. We clarify the expandable performance of 2.5 mm-DESs for very small target vessels with reference diameter <2.2 mm in vitro and vivo study. We studied 3 pieces in each kind of DES (Sirolimus-eluting stent; SES, Paclitaxel-eluting stent; PES, Zotarolimus-eluting stent; ZES and Everolimus-eluting stent; EES) in vitro and vivo study of the porcine coronary artery with reference diameter <2.2 mm. By using the delivery balloon, each stent was initially dilated with 3.5 atm. And the pressure of 0.5 atm. was applied until it reached the maximum pressure of 12 atm. The minimum pressure of the full expanded stent balloon was estimated as the minimum expandable pressure. The stent-inner diameter and area on each pressure were measured by IVUS. The average minimum expandable pressure (atm.) in vitro/vivo was 4.7/4.5 in SES, 7.2/6.8 in PES, 4.3/4.5 in ZES and 3.8/3.8 in EES. The inner diameter (mm) in vitro/vivo at minimum expandable pressure was 1.81 ± 0.07/1.84 ± 0.05 in SES, 2.31 ± 0.10/2.13 ± 0.13 in PES, 2.41 ± 0.13/1.98 ± 0.31 in ZES and 2.13 ± 0.11/1.88 ± 0.22 in EES. The stent inner-diameter (mm) of DESs at 8 atm. in vivo was 2.16/2.21/2.45/2.25 in SES/PES/ZES/EES. All kinds of DES could be delivered to very small target vessels with reference diameter <2.2 mm at the minimum expandable pressure in vivo study, but the stent which presented adequate stent inner-diameter at 8 atm. was only SES. We have to implant the 2.5 mm-DESs for very small target vessels according to the data based on this expandability of DESs to bail out threatening occlusion due to coronary dissection or elastic recoil.

No abstract